Delivery strategies for gene therapy of chronic heart failure

doi:10.3877/cma.j.issn.1674-0785.2018.03.008

Abstract

Abstract:

Chronic heart failure (CHF) is still the leading cause of morbidity and mortality worldwide, causing a great economic burden to the society. Although conventional therapy has a substantial role in reducing mortality from heart failure, the efficacy of novel pharmacologic agents and surgery in extending the 5-year survival rate is not satisfactory. Therefore, it is necessary to develop new therapies for this disease. Gene therapy was introduced in 1970s with the development of recombinant DNA technology. Thanks to the recent progress in myocardial metabolism research and the application of vector based gene transfer strategies in animal models and humans, gene therapy would probably be an ideal treatment alternative for CHF. Over the last two decades, much research has been done about gene therapy for heart failure with regard to different genes, different signal transduction pathways, and different delivery methods. As a result, gene therapy of advanced heart failure has become possible. The main goal of gene therapy for CHF is to inhibit apoptosis, reduce the undesirable remodeling, and increase the contractility through the most efficient cardiomyocyte transfection. In this paper, we will review various gene transfer technologies in ischemic heart disease and heart failure models, and discuss the advantages and disadvantages of these strategies in vector-mediated cardiac gene delivery, with emphasis put on the cardiac surgery with recirculating delivery system, a high efficiency approach.

Key words: Cardiac surgery with recirculating delivery, Gene delivery methods, Gene therapy, Cardiac, Chronic heart failure

Zhiqiang Yin, Wanhong Xing, Jie Ma, Jianxin Yang. Delivery strategies for gene therapy of chronic heart failure[J]. Chinese Journal of Clinicians(Electronic Edition), 2018, 12(03): 160-163.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2018.03.008

https://zhlcyszz.cma-cmc.com.cn/EN/Y2018/V12/I03/160

References 32

[1]	Katz MG, Fargnoli AS, Pritchette LA, et al. Gene delivery technologies for cardiac applications [J]. Gene Ther, 2012, 19(6): 659-669.
[2]	Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure [J]. N Engl J Med, 2001, 344(22): 1651-1658.
[3]	Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure [J]. N Engl J Med, 2001, 345(20): 1435-1443.
[4]	Hou J, Kang YJ. Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets [J]. Pharmacol Ther, 2012, 135(3): 337-354.
[5]	Wever-Pinzon O, Stehlik J, Kfoury AG, et al. Ventricular assist devices: pharmacological aspects of a mechanical therapy [J]. Pharmacol Ther, 2012, 134(2): 189-199.
[6]	Katz MG, Swain JD, Tomasulo CE, et al. Current strategies for myocardial gene delivery [J]. J Mol Cell Cardiol, 2011, 50(5): 766-776.
[7]	Fargnoli AS, Katz MG, Yarnall C, et al. A pharmacokinetic analysis of molecular cardiac surgery with recirculation mediated delivery of βARKct gene therapy: developing a quantitative definition of the therapeutic window [J]. J Card Fail, 2011, 17(8): 691-699.
[8]	Rengo G, Lymperopoulos A, Zincarelli C, et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure [J]. Circulation, 2009, 119(1): 89-98.
[9]	Rengo G, Lymperopoulos A, Leosco D, et al. GRK2 as a novel gene therapy target in heart failure [J]. J Mol Cell Cardiol, 2011, 50(5): 785-792.
[10]	Katz MG, Fargnoli AS, Williams RD, et al. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2＋) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy [J]. J Thorac Cardiovasc Surg, 2014, 148(3): 1065-1072, 1073e1061-1062; discussion1072-1073.
[11]	Kawase Y, Ladage D, Hajjar RJ. Rescuing the failing heart by targeted gene transfer [J]. J Am Coll Cardiol, 2011, 57(10): 1169-1180.
[12]	Katz MG, Fargnoli AS, Williams RD, et al. Surgical methods for cardiac gene transfer [J]. Future Cardiol, 2014, 10(3): 323-326.
[13]	Kornowski R, Fuchs S, Leon MB, et al. Delivery strategies to achieve therapeutic myocardial angiogenesis [J]. Circulation, 2000, 101(4): 454-458.
[14]	Katz MG, Fargnoli AS, Williams RD, et al. The road ahead: working towards effective clinical translation of myocardial gene therapies [J]. Ther Deliv, 2014, 5(1): 39-51.
[15]	Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution [J]. Cardiovasc Res, 1997, 36(1): 78-85.
[16]	Ladage D, Ishikawa K, Tilemann L, et al. Percutaneous methods of vector delivery in preclinical models [J]. Gene Ther, 2012, 19(6): 637-641.
[17]	Kawase Y, Ly HQ, Prunier F, et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure [J]. J Am Coll Cardiol, 2008, 51(11): 1112-1119.
[18]	Raake PW, Hinkel R, Muller S, et al. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors [J]. Gene Ther, 2008, 15(1): 12-17.
[19]	Boekstegers P, von Degenfeld G, Giehrl W, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins [J]. Gene Ther, 2000, 7(3): 232-240.
[20]	von Degenfeld G, Raake P, Kupatt C, et al. Selective pressure-regulated retroinfusion of fibroblast growth factor-2 into the coronary vein enhances regional myocardial blood flow and function in pigs with chronic myocardial ischemia [J]. J Am Coll Cardiol, 2003, 42(6): 1120-1128.
[21]	Katz MG, Fargnoli AS, Bridges CR. Myocardial gene transfer: routes and devices for regulation of transgene expression by modulation of cellular permeability [J]. Hum Gene Ther, 2013, 24(4): 375-392.
[22]	Hoshino K, Kimura T, De Grand AM, et al. Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres [J]. Gene Ther, 2006, 13(18): 1320-1327.
[23]	Byrne MJ, Power JM, Preovolos A, et al. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals [J]. Gene Ther, 2008, 15(23): 1550-1557.
[24]	Kaye DM, Preovolos A, Marshall T, et al. Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals [J]. J Am Coll Cardiol, 2007, 50(3): 253-260.
[25]	Bridges CR. ′Recirculating cardiac delivery′ method of gene delivery should be called ′non-recirculating′ method [J]. Gene Ther, 2009, 16(7): 939-940.
[26]	Kaplitt MG, Xiao X, Samulski RJ, et al. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector [J]. Ann Thorac Surg, 1996, 62(6): 1669-1676.
[27]	Raake P, von Degenfeld G, Hinkel R, et al. Myocardial gene transfer by selective pressure-regulated retroinfusion of coronary veins: comparison with surgical and percutaneous intramyocardial gene delivery [J]. J Am Coll Cardiol, 2004, 44(5): 1124-1129.
[28]	Katz MG, Fargnoli AS, Kendle AP, et al. Molecular Cardiac Surgery with Recirculating Delivery (MCARD): Procedure and Vector Transfer [J]. Methods Mol Biol, 2017, 1521: 271-289.
[29]	Kupatt C, Wichels R, Deiss M, et al. Retroinfusion of NFkappaB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs [J]. Gene Ther, 2002, 9(8): 518-526.
[30]	Boekstegers P, Kupatt C. Current concepts and applications of coronary venous retroinfusion [J]. Basic Res Cardiol, 2004, 99(6): 373-381.
[31]	Giordano FJ. Retrograde coronary perfusion: a superior route to deliver therapeutics to the heart? [J]. J Am Coll Cardiol, 2003, 42(6): 1129-1131.
[32]	Katz MG, Fargnoli AS, Swain JD, et al. AAV6-betaARKct gene delivery mediated by molecular cardiac surgery with recirculating delivery (MCARD) in sheep results in robust gene expression and increased adrenergic reserve [J]. J Thorac Cardiovasc Surg, 2012, 143(3): 720-726.

Please choose a citation manager

Content to export